
Opinion|Videos|April 4, 2025
Laboratory Monitoring Plans for Oral JAK Inhibitors
Experts discuss the necessary monitoring for patients prescribed JAK inhibitors, emphasizing regular assessments for safety and effectiveness, with adjustments in the monitoring plan based on factors such as smoking status and age.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What monitoring should be done once a patient is prescribed a JAK inhibitor? How often should a patient be monitored for safety and effectiveness?
a. Does smoking or age affect your monitoring plan?
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
5
























































